ARCUTIS BIOTHERAPEUTICS, INC. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ARCUTIS BIOTHERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $1.36M, a 2131.15% increase year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $1.07M, a 170.13% increase year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $1.48M, a 274.62% increase year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $61.00K, a 92.43% decline year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. stock issued during period, value, stock options exercised for fiscal 2025 was $4.60M, a 63.77% increase from fiscal 2024.
- ARCUTIS BIOTHERAPEUTICS, INC. stock issued during period, value, stock options exercised for fiscal 2024 was $2.81M, a 125.10% increase from fiscal 2023.
- ARCUTIS BIOTHERAPEUTICS, INC. stock issued during period, value, stock options exercised for fiscal 2023 was $1.25M, a 22.74% increase from fiscal 2022.
- ARCUTIS BIOTHERAPEUTICS, INC. stock issued during period, value, stock options exercised for fiscal 2022 was $1.02M, a 19.68% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $1.36M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $1.07M 10-Q · filed 2026-08-05 | |
| 2025-12-31 | $4.60M 10-K · filed 2026-02-25 | |
| 2025-09-30 | $1.48M 10-Q · filed 2025-10-28 | |
| 2025-06-30 | $61.00K 10-Q · filed 2026-08-05 | |
| 2025-03-31 | $395.00K 10-Q · filed 2026-08-05 | |
| 2024-12-31 | $2.81M 10-K · filed 2026-02-25 | |
| 2024-09-30 | $394.00K 10-Q · filed 2025-10-28 | |
| 2024-06-30 | $806.00K 10-Q · filed 2025-10-28 | |
| 2024-03-31 | $82.00K 10-Q · filed 2025-10-28 | |
| 2023-12-31 | $1.25M 10-K · filed 2026-02-25 | |
| 2023-09-30 | $867.00K 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $74.00K 10-Q · filed 2024-11-06 | |
| 2023-03-31 | $100.00K 10-Q · filed 2024-11-06 | |
| 2022-12-31 | $1.02M 10-K · filed 2025-02-25 | |
| 2022-09-30 | $494.00K 10-Q · filed 2023-11-03 | |
| 2022-06-30 | $156.00K 10-Q · filed 2023-11-03 | |
| 2022-03-31 | $260.00K 10-Q · filed 2023-11-03 | |
| 2021-12-31 | $1.26M 10-K · filed 2024-02-27 | |
| 2021-09-30 | $63.00K 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $710.00K 10-Q · filed 2022-11-08 | |
| 2021-03-31 | $325.00K 10-Q · filed 2022-11-08 | |
| 2020-12-31 | $430.00K 10-K · filed 2023-02-28 | |
| 2020-09-30 | $34.00K 10-Q · filed 2021-11-04 | |
| 2020-06-30 | $25.00K 10-Q · filed 2021-11-04 | |
| 2020-03-31 | $152.00K 10-Q · filed 2021-11-04 | |
| 2019-12-31 | $9.00K 10-K · filed 2022-02-22 | |
| 2019-09-30 | $9.00K 10-Q · filed 2020-11-05 | |
| 2018-12-31 | $43.00K 10-K · filed 2021-02-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |